Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 7/20 | 0.36 |
| ▸ | GABRG2 | P18507 | 7/20 | 0.36 |
| ▸ | GABRB3 | P28472 | 7/20 | 0.36 |
| ▸ | GABRA5 | P31644 | 7/20 | 0.36 |
| ▸ | GABRA3 | P34903 | 7/20 | 0.36 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.36 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.35 |
| ▸ | NOS2 | P35228 | 1/20 | 0.35 |
| ▸ | USP8 | P40818 | 1/20 | 0.34 |
| ▸ | USP7 | Q93009 | 1/20 | 0.34 |
| ▸ | KIF11 | P52732 | 1/20 | 0.33 |
| ▸ | MAT2A | P31153 | 1/20 | 0.32 |
| ▸ | MBOAT4 | Q96T53 | 1/20 | 0.32 |
| ▸ | CTSS | P25774 | 1/20 | 0.32 |
| ▸ | CTSK | P43235 | 1/20 | 0.32 |
| ▸ | SYK | P43405 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2159069 | 0.78 | ALDH1A1 (0.36) | TRPV4SLC6A4NOS2MAT2ACTSS | |
| SCHEMBL25253794 | 0.78 | TRPV4 (0.35) | TRPV4SLC6A4NOS2MAT2AMBOAT4 | |
| SCHEMBL30032746 | 0.78 | ALDH1A1 (0.36) | TRPV4SLC6A4NOS2MAT2ACTSS | |
| SCHEMBL23559730 | 0.78 | KDM4E (0.36) | TRPV4SLC6A4NOS2USP8MAT2A | |
| SCHEMBL30593099 | 0.78 | TRPV4 (0.35) | TRPV4SLC6A4NOS2MAT2AMBOAT4 | |
| SCHEMBL2634551 | 0.78 | NOTUM (0.36) | TRPV4SLC6A4NOS2MAT2AMBOAT4 | |
| SCHEMBL25985633 | 0.78 | TRPV4 (0.32) | TRPV4MAT2ACTSSSYKKDM4E | |
| SCHEMBL24108410 | 0.74 | RXRA (0.34) | TRPV4SLC6A4NOS2MAT2AALDH1A1 | |
| SCHEMBL30546007 | 0.74 | USP8 (0.43) | USP8USP7CTSSCTSKKDM4E | |
| SCHEMBL29043026 | 0.74 | USP8 (0.43) | USP8USP7CTSSCTSKKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12492181-B2 | Gem-disubstituted piperidine melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof | Crinetics Pharmaceuticals, Inc. (US) | 2025-12-09 | — | — | US | disclosed |
| US-12479825-B2 | Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof | Crinetics Pharmaceuticals, Inc. (US) | 2025-11-25 | — | — | US | disclosed |
| CN-115335369-B | GEM-disubstituted piperidine melanocortin subtype-2 receptor (MC 2R) antagonists and uses thereof | 克林提克斯医药股份有限公司 | 2024-07-02 | — | — | CN | disclosed |
| US-20230135560-A1 | GEM-DISUBSTITUTED PIPERIDINE MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONISTS AND USES THEREOF | Crinetics Pharmaceuticals, Inc. | 2023-05-04 | — | — | US | disclosed |
| US-20230015914-A1 | MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONISTS AND USES THEREOF | Crinetics Pharmaceuticals, Inc. | 2023-01-19 | — | — | US | disclosed |
| CN-115335369-A | GEM-disubstituted piperidine melanocortin subtype-2 receptor (MC 2R) antagonists and uses thereof | 克林提克斯医药股份有限公司 | 2022-11-11 | — | — | CN | disclosed |
| EP-4054583-A1 | MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONISTS AND USES THEREOF | Crinetics Pharmaceuticals, Inc. (US) | 2022-09-14 | — | — | EP | disclosed |
| WO-2021126693-A1 | GEM-DISUBSTITUTED PIPERIDINE MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONISTS AND USES THEREOF | Crinetics Pharmaceuticals, Inc. (US) | 2021-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12479825-B2 | Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof | MC3R, MC1R, MC2R | GABRA1 194/4885GABRG2 272/4885GABRB3 188/4885 |
| US-20230135560-A1 | GEM-DISUBSTITUTED PIPERIDINE MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONISTS AND USES THEREOF | MC1R, MC3R, MC2R | GABRA1 252/4885GABRG2 189/4885GABRB3 207/4885 |
| US-12492181-B2 | Gem-disubstituted piperidine melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof | MC1R, MC3R, MC2R | GABRA1 252/4885GABRG2 189/4885GABRB3 207/4885 |
| US-20230015914-A1 | MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONISTS AND USES THEREOF | MC3R, MC1R, MC2R | GABRA1 194/4885GABRG2 272/4885GABRB3 188/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.